The First Cell: And the Human Costs of Pursuing Cancer to the Last, Azra Raza
"...from 2002 to 2014, seventy-two new anticancer drugs gained FDA approval; they prolonged survival by 2.1 months. Of eighty-six cancer therapies for solid tumors approved between 2006 and 2017, the median gain in overall survival was 2.45 months. Of the cancer drugs approved during the past two decades, 70 percent of them were at best useless, showing no measurable survival benefit. Between 30 and 70 percent of the drugs may actually be harmful to patients. A study published in the British Medical Journal showed that thirty-nine of sixty-eight cancer drugs approved by the European regulators between 2009 and 2013 showed no improvement in survival or quality of life over existing treatment, placebo, or in combination with other agents."
"...from 2002 to 2014, seventy-two new anticancer drugs gained FDA approval; they prolonged survival by 2.1 months. Of eighty-six cancer therapies for solid tumors approved between 2006 and 2017, the median gain in overall survival was 2.45 months. Of the cancer drugs approved during the past two decades, 70 percent of them were at best useless, showing no measurable survival benefit. Between 30 and 70 percent of the drugs may actually be harmful to patients. A study published in the British Medical Journal showed that thirty-nine of sixty-eight cancer drugs approved by the European regulators between 2009 and 2013 showed no improvement in survival or quality of life over existing treatment, placebo, or in combination with other agents."